These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16625144)

  • 81. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
    Wei HY; Yang CP; Cheng CH; Lo FS
    Transfusion; 2011 May; 51(5):949-54. PubMed ID: 21077910
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Bad liver and a broken heart.
    Coates TD
    Blood; 2014 Mar; 123(10):1434-6. PubMed ID: 24627546
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Deferasirox treatment may be associated with reversible renal Fanconi syndrome.
    Even-Or E; Becker-Cohen R; Miskin H
    Am J Hematol; 2010 Feb; 85(2):132-4. PubMed ID: 20052747
    [No Abstract]   [Full Text] [Related]  

  • 89. [Pathogenesis of transfusional iron overload and iron chelation therapy].
    Ozawa K
    Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719
    [No Abstract]   [Full Text] [Related]  

  • 90. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.
    Dell'Orto VG; Bianchetti MG; Brazzola P
    J Clin Pharm Ther; 2013 Dec; 38(6):526-7. PubMed ID: 23981248
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
    Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
    Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Transitioning Patients With Iron Overload From Exjade to Jadenu.
    Tinsley SM; Hoehner-Cooper CM
    J Infus Nurs; 2018; 41(3):171-175. PubMed ID: 29659464
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
    Miyazawa K; Ohyashiki K; Urabe A; Hata T; Nakao S; Ozawa K; Ishikawa T; Kato J; Tatsumi Y; Mori H; Kondo M; Taniguchi J; Tanii H; Rojkjaer L; Omine M
    Int J Hematol; 2008 Jul; 88(1):73-81. PubMed ID: 18597054
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
    Quarta A; Melpignano A; Quarta G
    Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.
    Soummer A; Mathonnet A; Scatton O; Massault PP; Paugam A; Lemiale V; Mira JP; Dannaoui E; Cariou A; Lortholary O
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1585-6. PubMed ID: 18212106
    [No Abstract]   [Full Text] [Related]  

  • 97. Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
    Karimi M; Avazpour A; Haghpanah S; Toosi F; Badie A
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):e11-e14. PubMed ID: 27548339
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
    Huang WF; Chou HC; Tsai YW; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
    Masera N; Rescaldani C; Azzolini M; Vimercati C; Tavecchia L; Masera G; De Molfetta V; Arpa P
    Haematologica; 2008 Jan; 93(1):e9-10. PubMed ID: 18166775
    [No Abstract]   [Full Text] [Related]  

  • 100. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
    Pongtanakul B; Viprakasit V
    Blood Cells Mol Dis; 2013 Aug; 51(2):96-7. PubMed ID: 23566753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.